Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the α-emitting radionuclides 212Bi or 211At
- 30 April 2004
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 31 (3) , 357-364
- https://doi.org/10.1016/j.nucmedbio.2003.08.011
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Magic bullets hit the targetNature, 2002
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood, 2000
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac [see comments]Blood, 1995
- Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasThe Lancet, 1995
- PROLONGATION OF GRAFT SURVIVAL IN PRIMATE ALLOGRAFT TRANSPLANTATION BY YTTRIUM-90-LABELED ANTI-TAC IN CONJUNCTION WITH GRANULOCYTE COLONY-STIMULATING FACTORTransplantation, 1992
- USE OF YTTRIUM-90-LABELED ANTI-TAC ANTIBODY IN PRIMATE XENOGRAFT TRANSPLANTATIONTransplantation, 1990
- Multichain Interleukin-2 Receptor: A Target for Immunotherapy in LymphomaJNCI Journal of the National Cancer Institute, 1989
- THE MULTI-SUBUNIT INTERLEUKIN-2 RECEPTORAnnual Review of Biochemistry, 1989
- A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptorNature, 1982